<!DOCTYPE html>
<html lang="" xml:lang="">
  <head>
    <title>Improving Precision and Power in Randomized Trials for COVID-19 Treatments Using Covariate Adjustment, for Binary, Ordinal, or Time to Event Outcomes</title>
    <meta charset="utf-8" />
    <meta name="author" content="David Benkeser, PhD MPH    Emory University  Department of Biostatistics and Bioinformatics " />
    <script src="index_files/header-attrs-2.6/header-attrs.js"></script>
    <link rel="stylesheet" href="xaringan-themer.css" type="text/css" />
  </head>
  <body>
    <textarea id="source">
class: left, middle, inverse, title-slide

# <span style="font-size: 70%;">Improving Precision and Power in Randomized Trials for COVID-19 Treatments Using Covariate Adjustment, for Binary, Ordinal, or Time to Event Outcomes</span>
### <span style="font-size: 70%;">David Benkeser, PhD MPH</span> <br> <span style="font-size: 50%;"> Emory University<br> Department of Biostatistics and Bioinformatics </span>
### <span style="font-size: 50%;">Twitter:</span> <a href = 'https://twitter.com/biosbenk' style = 'color: white; font-size: 50%'><span class="citation">@biosbenk</span></a><br> <span style="font-size: 50%;">Slides:</span> <a href='https://bit.ly/cov19rct' style='color: white; font-size: 50%'>bit.ly/cov19rct</a> <br>

---




&lt;style type="text/css"&gt;
.remark-slide-content {
    font-size: 22px
}
&lt;/style&gt;

## The Dream Team

Joint work with:

* Iván Díaz (Weill-Cornell) and Alex Luedtke (UW) (co-first authors)
* Dan Scharfstein (Utah)
* Jodi Segal and Michael Rosenblum (JHU)

Benkeser, D., Díaz, I., Luedtke, A., Segal, J., Scharfstein, D., and Rosenblum, M. 
(In Press) Improving Precision and Power in Randomized Trials for COVID-19 Treatments Using Covariate Adjustment, for Binary, Ordinal, or Time to Event Outcomes. *Biometrics*. doi: [10.1111/biom.13377](https://doi.org/10.1111/biom.13377)

Slides based on talk given by M. Rosenblum at SCT2020.

---

## Motivation

* Over __800 randomized clinical trials__ (phase 2 and 3) of COVID-19 treatments registered on clinicaltrials.gov.
* March 2020: Request by the __U.S. Food and Drug Administration__ (FDA) for statistical analysis recommendation
for __COVID-19 treatment trials__.
* Primary outcomes in these trials often: __binary, ordinal, time-to-event__.
* We assessed potential value added by __covariate adjustment__ by simulating two-arm trials with 1:1 randomization
 comparing a hypothetical COVID-19 treatment versus standard of care.
* Simulations derived from data on over __500 patients hospitalized__ at New York Presbyterian Hospital, 
and a Centers for Disease Control and Prevention (CDC) preliminary description of 2449 cases.
* Submitted report in April, 2020, to FDA.

---

## Problem and goals

__Covariate adjustment in randomized trial:__
* Preplanned adjustment for baseline variables when estimating average or conditional treatment effect in primary efficacy analysis.
* Reduce required sample size to achieve desired power.

.red[Covariate adjustment often misunderstood and underutilized]

Our goals:
* Describe estimands, covariate-adjusted estimators, and implementation in R packages for these outcome types.
* Use simulations based on real data to demonstrate impact of covariate adjustment in hypothetical COVID-19 trials.
* Practical recommendations for implementation

---

## Main results

* The estimators that we consider are .green[robust to model misspecification].
* .green[Substantial precision gains] from using covariate adjustment.
* Equivalent to .green[4-18% reductions in required sample size] to achieve a desired power.
* Results shown for .green[a variety of estimands and sample sizes].
* We provide an R package and practical recommendations for implementing covariate adjustment. 

---

background-color: #012169
class: title-slide, center, inverse, middle

&lt;h1&gt; Background &lt;/h1&gt;

---

background-color: #84754e
class: title-slide, left, inverse, middle

*The statistical emphasis on covariate adjustment is quite complex and often poorly understood, and there remains confusion as to what is an appropriate statistical strategy.*

&lt;a href = 'https://doi.org/10.1002/sim.1296' style = 'color: white; font-size: 80%'&gt;Pocock et al. (2002)&lt;/a&gt;

&lt;br&gt; 

*A substantial and confusing variation exists in handling of baseline covariates in randomized controlled trials: a review of trials published in leading medical journals.*

&lt;a href = 'https://doi.org/10.1016/j.jclinepi.2009.06.002' style = 'color: white; font-size: 80%'&gt;Austin et al. (2010)&lt;/a&gt;

---

## Regulatory guidance

__ICH E9 Statistical Principles for Clinical Trials (1998)__

* *Pretrial deliberations should identify [covariates] expected to have an important influence on the [outcome], and should consider how to account for these in the analysis to improve precision.* 

__FDA draft guidance for continuous outcomes (2019)__
* *Sponsors can use ANCOVA to adjust for differences between treatment groups in relevant baseline variables to improve the power of [tests] and the precision of estimates of treatment effect* 

__FDA Guidance on COVID-19 treatment and prevention trials (2020)__
* *To improve the precision [...] sponsors should consider adjusting for prespecified prognostic baseline covariates [...] in the primary efficacy analysis and should propose methods of covariate adjustment.*

---

## Related work

__Many__ statisticians have been singing praise of covariate adjustment.

[Yang and Tsiatis, 2001](https://doi.org/10.1198/000313001753272466); [Zhang et al. 2008](https://doi.org/10.1111/j.1541-0420.2007.00976.x); [Tsiatis et al. 2008](10.1002/sim.3113); [Rubin and van der Laan, 2008](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2669310/); [Zhang and Gilbert 2010](https://doi.org/10.2202/1948-4690.1002); [Moore et al. 2011](https://doi.org/10.1002/sim.4301); [Tian et al. 2012](https://doi.org/10.1093/biostatistics/kxr050); [Zhang 2014](https://doi.org/10.1007/s10985-014-9291-y); [Zheng et al. 2015](https://biostats.bepress.com/ucbbiostat/paper339/); [Vermuelen et al. 2015](https://doi.org/10.1002/sim.6386); 
[Wager et al. 2016](https://doi.org/10.1073/pnas.1614732113); [Zhang and Ma, 2019](https://doi.org/10.1002/sim.8054); [Jiang et al. 2019](https://doi.org/10.1080/01621459.2018.1527226).

---

background-color: #012169
class: title-slide, center, inverse, middle

&lt;h1&gt; Methods &lt;/h1&gt;

---

## Estimands

We focus on __marginal (ITT) treatment effects__ -- contrasts between outcome distributions if all were assigned to treatment versus control. 

__Binary outcomes:__

* risk difference/ratio, odds ratio.

__Ordinal outcomes:__

* difference in means, Mann-Whitney\*, 
average cumulative log-odds ratio.

__Survival outcomes:__ 
* difference in restricted mean survival &lt;time&gt;&lt;/time&gt;, difference/ratio in survival probabilities


.footnote[\* = probability that outcome under treatment is better than outcome under control with ties broken at random]

---

## Estimands

Because treatment is .green[randomized], these effects can be estimated using .green[simple estimators].

* E.g., sample proportions/means, Mann-Whitney U statistic, Kaplan-Meier

.red[However], these approaches .red[ignore prognositc baseline variables]. Incorporating such variables .green[improves precision].

* In the case of missing outcomes, can also weaken censoring assumptions.

We present a covariate-adjusted estimator of each estimand that leverages prognostic variables. 
* For ordinal outcomes, novel covariate adjusted estimators.

---

## Simulations (survival outcomes)

Patient data re-sampled with replacement from 500 patients hospitalized at Weill Cornell Medicine New York Presbyterian Hospital.

* Simulated sample sizes n = 100, 200, 500, and 1000. 
* Hypothetical treatment variable drawn independent of all other data
* To simulate positive treatment effect: add independent draw from a `\(\chi^2\)` with 4 d.f. to each treatment arm participant's outcome
* Censoring: 5% censored completely at random; censoring time from uniform distribution on 1,...,14.

---

## Simulations (ordinal outcomes)

Patient data distribution mimicks distribution from hospitalized, COVID-19 positive patients in [CDC MMWR](https://www.cdc.gov/mmwr/volumes/69/wr/mm6912e2.htm). 

* Ordinal outcome: 1=death; 2=survival with ICU admission; 3=survival without ICU admission. 
* Baseline variable: Age category.
* Simulated sample sizes n = 100, 200, 500, and 1000. 
* Hypothetical treatment variable drawn independent of all other data.
* Simulated treatment impacted ICU admission, but not death.
* No censoring (though methods can handle)

---
background-color: #012169
class: title-slide, center, inverse, middle

&lt;h1&gt; Results &lt;/h1&gt;

---

## Results (survival outcomes)

.pull-left[

__Restricted Mean Survival Time__ 

|      n | Est. | Power | MSE | RE |
|:-------|:----------|:-----:|:---:|:--:|
|100  | Unadj. | 0.09 | 53.7 | 1.00 |
|100  | Adj.   |  0.15 | 51.0  | 0.95 |
|200  | Unadj. | 0.33 | 62.7  | 1.00 |
|200  | Adj.   |  0.40 | 56.4  | 0.90 |
|500  | Unadj. | 0.74 | 72.9  | 1.00 |
|500  | Adj.   | 0.82 | 62.2  | 0.85 |
|1000 | Unadj. |  0.96 | 76.5  | 1.00 |
|1000 | Adj.   |  0.98 | 63.5   | 0.83 | 

]

.pull-right[

&lt;br&gt; 

* True effect = reduction in 1 day
* Improved MSE (mostly due to variance) and power at all sample sizes.
* 5-17% reduction in sample size possible to achieve same power as with unadjusted estimator.
* Similar results observed for all survival estimands.

]

---

## Results (ordinal outcomes)

.pull-left[

__Difference in Means__

| n | Est. | Effect | Power | MSE |  RE |  
|:-------|:----------|:-----:|:---:|:--:|:--:|
| 100 | Unadj. | 0.30 | 0.47 | 2.2 |  1.00 |
| 100 | Adj. | 0.30 | 0.55 | 1.9 |  0.85 |
| 200 | Unadj. | 0.30 | 0.78 | 1.2 |  1.00 |
| 200 | Adj. | 0.30 | 0.84 | 1.0 | 0.87 |
| 500 | Unadj. | 0.20 | 0.81 | 0.5 | 1.00 |
| 500 | Adj. | 0.20 | 0.86 | 0.4 |  0.89 |
| 1000 | Unadj. | 0.14 | 0.84 | 0.2 | 1.00 |
| 1000 | Adj. | 0.14 | 0.87 | 0.2 | 0.89 |

]

.pull-right[

&lt;br&gt; 

* True effect chosen so that t-test has close to 80% power. 
* Improved MSE (mostly due to variance) and power at all sample sizes.
* 11-15% reduction in sample size possible to achieve same power as with unadjusted estimator.
* Similar results observed for all other ordinal and binary estimands.

]

---

## Software

`R` packages
* Ordinal Outcomes: [`drord`](https://github.com/benkeser/drord)
* Survival Outcomes: [`survtmlerct`](https://github.com/idiazst/survtmlerct)

---

## Other recommendations

__Estimand when the outcome is ordinal__ 
* .green[+] difference between means or Mann-Whitney 
* .red[-] log odds ratios

__Covariate adjustment__
* .green[+] Adjust for prognostic baseline variables.
* Approach should be specified before the trial is started 

__Confidence intervals (CI) and hypothesis testing__ 
* .green[+] Nonparametric bootstrap (BCa), 10,000 replicates for CI.
* Hypothesis tests: invert confidence interval or permutation.

---

## Other recommendations

__Use Information Monitoring__

* Final analysis time based on the information accrued. 
* Precision gains from covariate adjustment translate into faster information accrual and shorter trial duration.
* [Monoclonal antibody substudies of ACTIV-3 trial discontinued](https://www.niaid.nih.gov/news-events/statement-nih-sponsored-activ-3-clinical-trial-closes-enrollment-two-sub-studies) for futility based on severity-adjusted analysis.

__Missing covariates__

* Impute based only on data from observed covariates. 

__Missing outcomes__ 

* Use doubly robust methods and sensitivity analyses.

---

## Other recommendations

__Plot CDF and PMF when outcome is ordinal__

* Covariate adjusted estimate for each study arm.
* Pointwise and simultaneous confidence intervals displayed.

![](example_plots.png)

---

background-color: #012169
class: title-slide, center, inverse, middle

&lt;h1&gt; Questions? &lt;/h1&gt;
    </textarea>
<style data-target="print-only">@media screen {.remark-slide-container{display:block;}.remark-slide-scaler{box-shadow:none;}}</style>
<script src="https://remarkjs.com/downloads/remark-latest.min.js"></script>
<script>var slideshow = remark.create();
if (window.HTMLWidgets) slideshow.on('afterShowSlide', function (slide) {
  window.dispatchEvent(new Event('resize'));
});
(function(d) {
  var s = d.createElement("style"), r = d.querySelector(".remark-slide-scaler");
  if (!r) return;
  s.type = "text/css"; s.innerHTML = "@page {size: " + r.style.width + " " + r.style.height +"; }";
  d.head.appendChild(s);
})(document);

(function(d) {
  var el = d.getElementsByClassName("remark-slides-area");
  if (!el) return;
  var slide, slides = slideshow.getSlides(), els = el[0].children;
  for (var i = 1; i < slides.length; i++) {
    slide = slides[i];
    if (slide.properties.continued === "true" || slide.properties.count === "false") {
      els[i - 1].className += ' has-continuation';
    }
  }
  var s = d.createElement("style");
  s.type = "text/css"; s.innerHTML = "@media print { .has-continuation { display: none; } }";
  d.head.appendChild(s);
})(document);
// delete the temporary CSS (for displaying all slides initially) when the user
// starts to view slides
(function() {
  var deleted = false;
  slideshow.on('beforeShowSlide', function(slide) {
    if (deleted) return;
    var sheets = document.styleSheets, node;
    for (var i = 0; i < sheets.length; i++) {
      node = sheets[i].ownerNode;
      if (node.dataset["target"] !== "print-only") continue;
      node.parentNode.removeChild(node);
    }
    deleted = true;
  });
})();
(function() {
  "use strict"
  // Replace <script> tags in slides area to make them executable
  var scripts = document.querySelectorAll(
    '.remark-slides-area .remark-slide-container script'
  );
  if (!scripts.length) return;
  for (var i = 0; i < scripts.length; i++) {
    var s = document.createElement('script');
    var code = document.createTextNode(scripts[i].textContent);
    s.appendChild(code);
    var scriptAttrs = scripts[i].attributes;
    for (var j = 0; j < scriptAttrs.length; j++) {
      s.setAttribute(scriptAttrs[j].name, scriptAttrs[j].value);
    }
    scripts[i].parentElement.replaceChild(s, scripts[i]);
  }
})();
(function() {
  var links = document.getElementsByTagName('a');
  for (var i = 0; i < links.length; i++) {
    if (/^(https?:)?\/\//.test(links[i].getAttribute('href'))) {
      links[i].target = '_blank';
    }
  }
})();</script>

<script>
slideshow._releaseMath = function(el) {
  var i, text, code, codes = el.getElementsByTagName('code');
  for (i = 0; i < codes.length;) {
    code = codes[i];
    if (code.parentNode.tagName !== 'PRE' && code.childElementCount === 0) {
      text = code.textContent;
      if (/^\\\((.|\s)+\\\)$/.test(text) || /^\\\[(.|\s)+\\\]$/.test(text) ||
          /^\$\$(.|\s)+\$\$$/.test(text) ||
          /^\\begin\{([^}]+)\}(.|\s)+\\end\{[^}]+\}$/.test(text)) {
        code.outerHTML = code.innerHTML;  // remove <code></code>
        continue;
      }
    }
    i++;
  }
};
slideshow._releaseMath(document);
</script>
<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
(function () {
  var script = document.createElement('script');
  script.type = 'text/javascript';
  script.src  = 'https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-MML-AM_CHTML';
  if (location.protocol !== 'file:' && /^https?:/.test(script.src))
    script.src  = script.src.replace(/^https?:/, '');
  document.getElementsByTagName('head')[0].appendChild(script);
})();
</script>
  </body>
</html>
